Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more here.

Articles & Research
from hVIVO

Human Clinical Trials: A Tool in the Fight Against Infectious Diseases

International Clinical Trials, Autumn 2022, pages 94-97. © Samedan Ltd

RSV Vaccines/Prophylactics: Key learning from the RSV challenge model and efficacy of vaccines

Initial characteristics of respiratory viruses in symptomatic subjects during the pandemic, a cohort study

Immunomodulators and treatment of disease in the influenza human challenge model

Human Challenge Studies: Their Conduct and Safety Aspects

If there would be a survey of 100 clinical research professionals either from CRO or from Pharma/Biotech industry to explain what a human challenge study is, the most common answer...

Scientific Paper

Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled Trial

RSV Human Challenge Case Study

An international biotech company, headquartered in the EU approached hVIVO to explore the possibility of performing a RSV Phase IIa challenge study. The investigational product was a novel recombinant modified...

Infectious Diseases Blog – ‘The Pathogenda’ Part 5

In one of the most important discoveries in medicine this year, Epstein-Barr virus (EBV) has been collared as the link/early causal role in multiple sclerosis. Finding the virus underpinning multiple...

Infectious Diseases Blog – ‘The Pathogenda’ Part 4

So we know, or at least it is being widely reported, that depression and anxiety indices are raised worldwide, and most especially in High Income Countries (HIC). Whilst this is...

Scientific Paper

Human infection studies: Key considerations for challenge agent development and production